University College, London
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, University College, London sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).
University College, London: 8 sponsored US clinical trials, 4 recruiting.
University College, London sponsors 8 registered US clinical trials on ClinicalTrials.gov, 4 of them currently recruiting. 1 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Dentatorubral-Pallidoluysian Atrophy, with 1 trials.
Upper-quartile sponsor footprint
University College, London sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
8 total, page 1 of 1
A Trial Evaluating the Effect of NIO752 on Tau Synthesis Measured by a Process Known as SILK
NCT06372821
Dentatorubral-pallidoluysian Atrophy Natural History and Biomarkers Study
NCT06273150
Brentuximab Vedotin in Early Stage Hodgkin Lymphoma
NCT04685616
HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease
NCT02855476
Prostate Imaging Using MRI +/- Contrast Enhancement
NCT04571840
Gene Therapy for Haemophilia A.
NCT03001830
A Factor IX Gene Therapy Study (FIX-GT)
NCT03369444
Evaluating Dietary Intervention Before surgicaL Treatment for Epilepsy
NCT02261753
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 3 | 1 |
Therapeutic Areas
What is open in the University College, London pipeline
4 recruiting of 8 indexed (50% open).
Phase mix: 1 late (III/IV) vs 3 early (I/II) (early-phase heavy).
Top condition: Dentatorubral-Pallidoluysian Atrophy (1 trial), 8 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
University College, London: open-pipeline peers nationwide
Peers matched on 8 registered trials and 50% open enrollment, not the therapeutic-area sidebar.
University College, London sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 8 trials (± recruiting share)
- AB Science · 8 trials · 25% recruiting
- Abbott Point of Care · 8 trials · 25% recruiting
- Abeona Therapeutics · 8 trials · 0% recruiting
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · 8 trials · 38% recruiting
Sponsors near 50% open enrollment (± trial volume)
- 1200 Pharma · 50% recruiting · 2 trials
- 1ST Biotherapeutics · 50% recruiting · 2 trials
- 3ive Labs · 50% recruiting · 2 trials
- 60 Degrees Pharmaceuticals · 50% recruiting · 4 trials
Related
What to do with this University College, London page
8 registered trials is a research-attention snapshot, not an endorsement of University College, London or any single study.
- 4 of University College, London's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Dentatorubral-Pallidoluysian Atrophy is the condition University College, London studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Dentatorubral-Pallidoluysian Atrophy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
University College, London pipeline card: 8 registered trials from official public datasets.Report a data error.